We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 2 ACUITY trial met its primary safety endpoint ...
A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...
The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ACUITY ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback